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SLC26A2 -related dysplasias encompass a spectrum of diseases: from lethal
achondrogenesis type 1B (ACG1B; MIM #600972) and atelosteogenesis
type 2 (AO2; MIM #256050) to classical diastrophic dysplasia (cDTD;
MIM #222600) and recessive multiple epiphyseal dysplasia (rMED; MIM
#226900). This study aimed at characterizing clinically, radiologically and
molecularly 14 patients affected by non-lethal SLC26A2 -related dysplasias
and at evaluating genotype–phenotype correlation. Phenotypically, eight
patients were classified as cDTD, four patients as rMED and two patients
had an intermediate phenotype (mild DTD – mDTD, previously ‘DTD
variant’). The Arg279Trp mutation was present in all patients, either in
homozygosity (resulting in rMED) or in compound heterozygosity with the
known severe alleles Arg178Ter or Asn425Asp (resulting in DTD) or with
the mutation c.727-1G>C (causing mDTD). The ‘Finnish mutation’,
c.-26+2T>C, and the p.Cys653Ser, both frequent mutations in
non-Portuguese populations, were not identified in any of the patients of
our cohort and are probably very rare in the Portuguese population. A
targeted mutation analysis for p.Arg279Trp and p.Arg178Ter in the
Portuguese population allows the identification of approximately 90% of
the pathogenic alleles.
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Clinical and molecular characterization of DTD
SLC26A2 -related chondrodysplasias are a group
of skeletal disorders because of recessive muta-
tions in the ‘diastrophic dysplasia’ (DTD) sulfate
transporter (DTDST). DTD(MIM #222600) is the
most known phenotype of the SLC26A2 muta-
tion spectrum, which spans from lethal achondro-
genesis type 1B (ACG1B; MIM #600972) and
atelosteogenesis type 2 (AO2; MIM #256050)
to classical DTD (cDTD) and recessive multi-
ple epiphyseal dysplasia (rMED; MIM #226900).
No reliable data exist regarding the frequency of
SLC26A2 -related chondrodysplasias, but these dis-
orders are generally believed to occur in approxi-
mately 1:100,000 (1).
Clinically, DTD is characterized by short-limbed
dwarfism, normal-sized skull, cleft palate, cystic
ear swelling, small chest, protuberant abdomen,
spinal deformities, large joint contractures, radius
dislocation, hitchhiker thumbs and clubfeet (2, 3).
Radiographic findings include cervical kyphosis,
bell-shaped chest, hypoplastic ilia with flat acetab-
ula, shortened long bones with metaphyseal flaring,
flat epiphyses, kyphoscoliosis with caudal reduc-
tion of interpeduncular distance, bowed radius
and tibia brachydactyly, hitchhiker thumb, ulnar
deviation of the fingers, shortness of the first
metacarpal, delta-shaped proximal and middle pha-
langes (2, 3).
rMED is characterized by childhood-onset joint
pain at hips and knees, mild brachydactyly,
mildly shortened or normal stature and congenital
clubfoot in some cases (4).
The SLC26A2 gene (MIM #606718, locus 5q32-
q33.1) consists of a 5′ untranslated exon with reg-
ulatory functions and two coding exons. SLC26A2
encodes a sulfate transporter that belongs to the
family of anion exchangers known as solute car-
rier family 26 (SLC26) (5). The sulfate/chloride
antiporter is predicted to have 12 transmem-
brane domains and a carboxy-terminal, cytoplas-
mic, moderately hydrophobic domain. This trans-
porter is crucial for the uptake of inorganic sulfate
into chondrocytes in order to maintain adequate
levels of intracellular sulfate and allowing proper
sulfation of the proteoglycans (6, 7). The SLC26A2
gene is expressed not only in developing carti-
lage in human fetuses but also in a wide variety
of other tissues (5, 7). Phenotypic manifestations
of DTDST mutations are not restricted to skeleton
but involve other organs containing cartilage tissue
(e.g. external ears and larynx) and the ligamentous
apparatus (e.g tendons and joint capsules).
Impaired activity of the sulfate transporter in
chondrocytes and fibroblasts causes intracellular
sulfate depletion, which leads to insufficiently
sulfated proteoglycans (8, 9). Hence, cartilage
has reduced total sulfate content and contains
undersulfated glycosaminoglycans (9–11), which
compromise enchondral bone formation (7, 12).
Recent studies in transgenic mice showed that
proteoglycans are not only structural components
of cartilage architecture, but also play a dynamic
role in the regulation of chondrocyte growth and
differentiation (13).
The four most common SCL26A2 mutations
are p.Arg279Trp, c.-26+2T>C (also known as
‘Finnish allele’), p.Arg178Ter and p.Cys653Ser.
These mutations account for 70% of disease alle-
les (66% in DTD cases and 90% in rMED cases)
and can be detected by restriction enzyme diges-
tion and gel electrophoresis screening. Sequence
analysis may detect rarer mutations (1, 14).
The predicted severity of the mutations can
be correlated with the residual activities of
the sulfate transporter and the severity of the
phenotypes (10–12, 14–17). In humans, corre-
lations between SLC26A2 mutations and clin-
ical phenotypes have been described: ‘severe’
mutations (premature truncation of the protein
or mutations in transmembrane domains) lead
to the absence/minimal residual activity of the
sulfate transporter and homozygosity or com-
pound heterozygosity results in a severe phenotype
(ACG1B) (18). ‘Mild’ mutations (missense muta-
tion in non-transmembrane domain, cytoplasmic
tail of the protein or in the regulatory 5′-flanking
region) produce a protein with significant residual
activity, which leads to either rMED (‘mild’ muta-
tion in homozygosity) or to a mild form of DTD
(in association with a ‘severe’/‘moderate’ muta-
tion). Hence, dealing with a recessive disorder, the
milder mutation tends to ‘rescue’ the effect of a
severe mutation (14, 19).
In the current literature, all reports of large
series of patients with DTD are from Finland,
where most patients present homozygosity for the
‘Finnish mutation’. However, these conclusions
may not apply to other populations. This study
aimed at recruiting a cohort of DTD/rMED patients
from Portugal and at studying their clinical and
molecular aspects.
Patients and methods
Patients
The four main Portuguese Services of Medical
Genetics and four Orthopedics Services were con-
tacted in order to recruit, at a national level,
patients already diagnosed as DTD or rMED or
suspected of being affected by these disorders.
We invited the physicians in those services to
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fill in a screening protocol that we designed with
a list of signs and symptoms compatible with
SLC26A2 -related, non-lethal, skeletal dysplasias
(limb shortening, normal-sized skull, trunk short-
ening, hitchhiker thumbs, small chest, protuberant
abdomen, contractures of large joints, dislocation
of the radius, cleft palate, cystic ear swelling in
the neonatal period, ulnar deviation of the fingers,
gap between the first and second toes, clubfoot
and flat hemangiomas of the forehead). Fourteen
patients were selected for detailed clinical exami-
nation and X-ray review. All patients were referred
by the Medical Genetics Services; eight of them
were already in follow-up in the Orthopedics Ser-
vices (and six patients were not being followed in
Orthopedics).
A clinical protocol concerning family and per-
sonal history and tailored physical exam was per-
formed in all patients. Heights were plotted against
charts developed from Finnish DTD patients (20).
Skeletal survey was requested and analyzed in all
of them.
The clinical protocol, the photos and the X-rays
were reviewed by the authors with the largest
experience on these disorders (ASF and LB), who
confirmed the diagnosis. Thereafter, the selected
patients were screened for SLC26A2 (DTDST)
mutations. All patients with the clinical diagnosis
made by us were mutation positive.
Molecular analysis
The SLC26A2 gene was amplified by polymerase
chain reaction (PCR) and screened for the four
most common mutations by restriction enzyme
digestion and gel electrophoresis. Subsequently,
selective fragments of the gene were analyzed
by bi-directional fluorescent direct sequencing.
Results were confirmed in a second amplification
product. If both mutations were not identified, the
entire gene was then amplified by PCR and ana-
lyzed by bi-directional fluorescent direct sequenc-
ing. Mutations have been classified according to
GenBank accession number U14528. Nucleotide
1 has been counted as the first nucleotide of
the sequence, with nucleotide 28 being the first
nucleotide of the translation initiation codon.
Results
Clinical characterization
The clinical data of the patients can be consulted
in Table 1. Fourteen patients were recruited, nine
males and five females, with ages varying between
2 and 40 years (17 years on average). Phenotyp-
ically, eight patients were classified as cDTD,
four patients as rMED and two patients presented
with an intermediate phenotype between DTD and
rMED (mild DTD, mDTD). All patients were cau-
casian and from ancient Portuguese descent. No
history of consanguinity was reported in any of
the patients.
In order to accurately evaluate the growth of the
patients, their height was plotted against graphics
designed specifically for DTD patients (20). How-
ever, these graphics have been designed based on
a population of Finnish patients most of whom are
homozygous for the ‘Finnish’ mutation, which is
mild. Moreover, the average height of the back-
ground Portuguese population is lower than that
of northern Europeans. Patients with cDTD in our
series were indeed under the 25th centile (some of
them even under the 10th centile). Patients with
mDTD were around the 25th centile and patients
with rMED were above the 50th centile.
Concerning the craniofacial abnormalities, facial
dysmorphism (high forehead, forehead heman-
gioma, downslanting and short palpebral fissures,
long nose with hypoplastic alae nasi and small
mouth) was only detected in cDTD. Patients with
both cDTD and mDTD consistently presented dys-
plastic ears and hoarse voice (possible because of
changes in the laryngeal cartilage structures). Cleft
palate was more common in cDTD (37.5% of the
patients) but, interestingly, one patient (P13) of the
rMED group presented bifid uvula.
All patients with DTD presented spine defor-
mities, the most common being cervical kyphosis.
Arthrosis of the hips was a common complaint in
patients older than 25 years.
Limb shortening, bowed diaphyses and contrac-
tures of large joints were present in all patients
with DTD, while only occasionally in patients with
rMED. The typical hand findings were striking in
cDTD but subtle in the mDTD. Clubfeet and short-
ened Achilles tendons were present in almost all
patients (DTD and rMED). However, the youngest
and also least affected patient of this cohort only
presented limitation of dorsiflexion of the feet.
Most patients underwent orthopedic surgery.
However, despite multiple surgeries of the feet, the
outcome was poor in most of them. Two patients
had surgery for spinal cord decompression because
of severe kyphoscoliosis. It has been recently
shown that early surgical intervention might be a
better option in many patients with DTD as brace
treatment does not prevent progression of spinal
deformities (21). Concerning quality of life, all
patients had limitations; the degree of autonomy
could not be predicted by their genotype. In
fact, different outcomes were observed in patients
with the same genotype. Possible explanations
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Fig. 1. Radiological features. Patients with classical diastrophic dysplasia (cDTD) present kyphoscoliosis, upper and lower limb
show shortened long bones with some metaphyseal flaring, bowed radius and tibia, hands with hitchhiker thumb with ulnar deviation
of the fingers, hypoplastic ilia with flat acetabula and clubfeet. Patients with mild diastrophic dysplasia (mDTD) present similar
but milder radiological presentation than cDTD. Patients with recessive multiple epiphyseal dysplasia show moderately shortened
long bones, hypoplastic ilia with flat acetabula and club feet.
could subside in the genetic background, medical
management, treatment options/timing/availability
and family support.
Concerning the X-Ray analysis (Fig. 1, Table 1),
we verified that all patients with cDTD presented
with skull of normal size, cervical kyphosis, short-
ened long bones with some metaphyseal flaring,
bowed radius and tibia, abnormalities of the hands
(with hitchhiker thumb with ulnar deviation of the
fingers being the most striking) and hypoplastic
ilia with flat acetabula. mDTD patients had similar
but milder radiological presentation. Patients with
rMED consistently presented with skull of normal,
moderately shortened long bones, hypoplastic with
flat acetabula ilia and club feet.
Molecular characterization
Molecular characterization of the patients is pre-
sented in Table 1. Four known mutations were
identified in our patients: c.559C>T (p.Arg178
Ter), c.727-1G>C (previously described as g.IVS
2-1G>C), c.862C>T (p.Arg279Trp) and c.1300
A>G (p.Asn425Asp) (Fig. 2).
Discussion
This paper reports the largest series of DTD
patients in a non-Finnish population. All patients
had short stature; however, the severity was
decreasing from cDTD to mDTD and to rMED.
Patients with DTD (both classical and mild) con-
sistently presented dysplastic ear and hoarse voice,
cervical kyphosis, limb shortening, bowed dia-
physis, contractures of the large joints, clubfeet
and shortened Achilles tendons. Hand findings
were more severe in cDTD than in mDTD and
hitchhiker thumbs were only identified in cDTD.
Patients with rMED commonly had clubfeet and
subtle hand finding (moderate brachydactyly with
ulnar deviation of the second finger).
Although specific features can be attributed to
the different phenotypes, it is interesting to note
that there is also an overlap between the different
phenotypes. This is shown here between DTD and
rMED (Fig. 3), but it is also true for the other
SLC26A6 -related dysplasias (between ACG1B
and AO2 and between AO2 and DTD) (22–26).
The spectrum of SLC26A2 -related dysplasias can
hence be described as a continuum, while also con-
tinuously expanding (27). Apart from the combi-
nation of different mutations in the SLC26A2 gene,
the variations in phenotypes could be due to mod-
ifiers of the SLC26A2 gene, to variations of other
genes involved in sulfate metabolism (6, 7, 13), as
well as to the genetic background and environ-
ment. The significant role of these factors can be
554
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Fig. 2. The sulfate transporter encoded by the SCL26A2 gene is represented as a horizontal bar; the 12 putative transmembrane
domains are shaded dark gray and the cytoplasmic domains are shaded light gray. The mutations identified in our patients are
shown: Arg178Ter – diamond; c.727-1G>C – arrow; Arg279Trp – circle; and Asn425Asp – triangle.
best appreciated in the two pairs of siblings of
the cohort (patients 5 and 6 and patients 13 and
14) with slightly different presentation and signif-
icantly different outcome while carrying the same
mutations. The older pair of sibs (patients 5 and
6), presenting with cDTD, have overlapping phe-
notypes except for the presence of scoliosis and
severe clubfeet in the eldest brother that has lim-
ited his ambulation. Both brothers were surgically
interventioned multiple times (five times the eldest
and seven times the youngest). The other pair of
sibs, affected with rMED, had more significantly
different phenotypes: besides a bifid uvula, the
elder brother had contracture of knees and clubfeet
that, together, restrained his ambulation. On the
contrary, his sister was very mildly affected and
the diagnosis could be suspected only by family
history and careful physical exam.
Four known mutations were identified in our
patients: c.559C>T (p.Arg178Ter), c.727-1G>C,
c.862C>T (p.Arg279Trp) and c.1300A>G (p.Asn
425Asp). The mutations p.Arg178Ter and p.Asn
425Asp are localized in transmembrane domains
(Fig. 1) and hence are predicted to cause a severe
disruption of the sulfate transporter function.
Mutation p.Arg178 Ter is a recurrent mutation that
results in ACG1B when homozygosity or com-
pounded with another severe mutation. Indeed,
functional studies have showed that sulfate trans-
porters bearing the p.Arg178X and p.Asn425Asp
mutations have residual activity of <10% com-
pared to the wild-type transporter (28). The mis-
sense mutation p.Arg279Trp occurs in an extracel-
lular loop. Indeed, functional analysis showed that
the DTDST transporters bearing that mutation had
39–62% activity compared to the wild type (16).
The c.727-1G>C, very rare in non-Portuguese
populations, is thought to interfere with the splic-
ing and has been described as pathogenic (29). The
presence of this mutation in 2 of 14 unrelated Por-
tuguese patients may indicate that this variant is
more common in the Portuguese population.
As previously reported, Arg279Trp, which is a
‘mild’ mutation (with significant sulfate transporter
function) in homozygosity, causes the phenotype
of rMED, but the association of this ‘mild’
mutation with a null mutation (Arg178Ter) or a
missense mutation in the transmembrane domain
Fig. 3. Clinical spectrum of SLC26A2 patients.
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(Asn425Asp) (both leading to the absence of
ST function) cause the intermediate phenotype of
DTD.
Our experience on molecular testing for
SLC26A2 (DTDST) mutations in 350 non-Finnish
non-Portuguese Caucasian chromosomes show
that four common mutations (p.Arg279Trp, p.Arg
178X, p.Cys653Ser and IVS1+2T>C or ‘Finnish’
mutation) account for about 70% of all pathogenic
alleles (30, 31), with p.Arg279Trp being present in
about 44% of alleles and the other three mutations
representing each about 9% of all pathogenic alle-
les. Although the patients presented here represent
only a sample (28 chromosomes) of Portuguese
patients with SLC26A2 -related dysplasias, it is
noteworthy that p.Arg279Trp accounted for 64%
and p.Arg178Ter for 25%. Thus, a targeted muta-
tion analysis for p.Arg279Trp and p.Arg178Ter
in the Portuguese population would be expected
to identify approximately 90% of the pathogenic
alleles.
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